AstraZeneca stock price forecast: GBX13,320 resistance as AZN holds steady near key level

Traders Union
All News
Financial News
AstraZeneca gains 0.14% to GBX13,228 today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Ciaran Ryan

12 hours ago

AstraZeneca stock price forecast: GBX13,320 resistance as AZN holds steady near key level — AstraZeneca gains 0.14% to GBX13,228 today

AstraZeneca (AZN) stock is trading at GBX13,228.00, up 0.14% for the session. The price currently sits above its key short-term moving averages, but medium- and longer-term trends remain mixed based on technical positioning.

AZN price prediction

24H 0.39%

GBX 13617

48H 0.57%

GBX 13641

7D 2.15%

GBX 13855.68

1M 0.32%

GBX 13606.85

3M 5.3%

GBX 14283.32

6M 17.29%

GBX 15909.82

12M 28.94%

GBX 17489.99

Detailed

Current price: GBX 13564 354.00 2.68%

Closed 06/04

Daily range 13168.00

13592.00

Weekly range 11232.00

13912.00

Highlights

AstraZeneca will withdraw Zoladex from Australia and certain international markets, shifting revenue exposure in those territories.
First-quarter 2026 oncology sales reached $6.8 billion, buoyed by strong demand and new product launches alongside additional European regulatory approvals.
Technical outlook is neutral to bearish, with weak momentum indicators and an expected range of GBX12,687.77–GBX13,768.23 signaling downside risk prevails.

Revenue outlook shifts as Zoladex withdrawal and new approvals reshape markets

AstraZeneca has announced the planned withdrawal of its key drug Zoladex (goserelin 3.6mg implant) from Australian and select international markets, citing commercial considerations rather than any safety or efficacy concerns. This development shifts supply and future revenue exposure in those territories, potentially affecting market share and investor sentiment. Meanwhile, the company reported oncology sales of $6.8 billion in the first quarter of 2026, reflecting robust demand for its core cancer therapies and new product launches. Recent regulatory moves, including expanded National Health Service coverage for Imfinzi in the UK and new approvals for Lokelma and Calquence in Europe, are likely to support future growth and reinforce the active market response to current corporate performance.

Mixed technical signals as momentum weakens despite key support levels

On the hourly chart, AZN is trading above its MA-20 at GBX13,150.00, while remaining below the MA-50 at GBX13,320.00 and the long-term MA-200 at GBX13,500.00. The Ichimoku Kijun line provides immediate support at GBX12,473.00. Momentum indicators show the MACD in a strong sell position, with the ADX also pointing to a sell bias. The RSI measures at 46.54, reflecting moderate weakness, while the Stoch RSI and BBP both register overbought readings. The CCI and Awesome Oscillator are neutral, highlighting mixed market signals alongside low volatility and a minor 30-point intraday gap.

Downside risk prevails as range trading persists and volatility bands tighten

For the short term, AZN is expected to trade within a volatility band of GBX12,687.77 to GBX13,768.23. The forecast assigns a 36% probability to an upward move, with a downside scenario considered more likely based on current indicators. The baseline case anticipates continued range-bound trading; however, a bullish breakout above resistance could trigger follow-on gains, while a breach below support would signal increased downside risk.

Viktoras Karapetjanc, Traders Union expert, highlights AstraZeneca’s active product management and robust oncology growth. He sees positive regulatory momentum and strong fundamentals underpinning confidence in the outlook. Near-term price action is mixed, but the fundamental narrative supports constructive sentiment despite technical indecision. Karapetjanc believes further expansion in core markets will sustain long-term growth. "Strategic product adjustments and recent regulatory wins reinforce my view that AstraZeneca remains well positioned for future upside."

Earlier, analysts noted that AstraZeneca faced persistent selling pressure and bearish momentum despite positive clinical developments. While recent price action shows some short-term stabilization, traders should monitor for a decisive move above the medium-term moving average to confirm a potential shift in directional bias.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.